Financial Analysis: Evogene (EVGN) versus Its Rivals

Evogene (NASDAQ: EVGN) is one of 21 public companies in the “Agricultural chemicals” industry, but how does it weigh in compared to its competitors? We will compare Evogene to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

35.5% of Evogene shares are held by institutional investors. Comparatively, 38.0% of shares of all “Agricultural chemicals” companies are held by institutional investors. 13.7% of shares of all “Agricultural chemicals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Evogene and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evogene -616.33% -27.15% -24.51%
Evogene Competitors -1,647.82% -18.02% -10.75%

Analyst Recommendations

This is a breakdown of current ratings for Evogene and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evogene 0 0 0 0 N/A
Evogene Competitors 171 572 645 38 2.39

As a group, “Agricultural chemicals” companies have a potential upside of 18.44%. Given Evogene’s competitors higher possible upside, analysts plainly believe Evogene has less favorable growth aspects than its competitors.

Risk and Volatility

Evogene has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Evogene’s competitors have a beta of 0.46, suggesting that their average stock price is 54% less volatile than the S&P 500.

Earnings & Valuation

This table compares Evogene and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evogene $3.38 million -$20.83 million -3.52
Evogene Competitors $3.12 billion $271.73 million 0.23

Evogene’s competitors have higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Evogene competitors beat Evogene on 7 of the 9 factors compared.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company’s Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company’s Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Stitch Fix  & LightInTheBox  Critical Survey
Stitch Fix & LightInTheBox Critical Survey
Head-To-Head Contrast: DavidsTea  vs. Sainsbury’s
Head-To-Head Contrast: DavidsTea vs. Sainsbury’s
Sinclair Broadcast Group  Expected to Announce Earnings of $0.73 Per Share
Sinclair Broadcast Group Expected to Announce Earnings of $0.73 Per Share
Comparing Revolution Lighting Technologies  and Energy Focus
Comparing Revolution Lighting Technologies and Energy Focus
HCP, Inc.  Receives $27.50 Consensus Price Target from Brokerages
HCP, Inc. Receives $27.50 Consensus Price Target from Brokerages
Brokerages Set Eni  Target Price at $30.75
Brokerages Set Eni Target Price at $30.75


Leave a Reply

© 2006-2018 Ticker Report. Google+.